Macrolides(continued)
▶Erythromycinis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(vardenafil). Adjust dose.
rTheoretical→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to increase the exposure to
pimozide. Avoid.rStudy→Also seeTABLE 9p. 849
▶Erythromycinis predicted to increase the exposure to
pimozide. Avoid.rTheoretical→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to slightly increase the exposure to
ponatinib. Monitor and adjustponatinibdose.oStudy
▶Clarithromycinis predicted to moderately increase the
exposure topraziquantel.nStudy
▶Clarithromycinis predicted to increase the exposure to
quetiapine. Avoid.rStudy
▶Erythromycinis predicted to increase the exposure to
quetiapine. Avoid.oStudy
▶Clarithromycinis predicted to increase the exposure to
ranolazine. Avoid.rStudy→Also seeTABLE 9p. 849
▶Erythromycinis predicted to increase the exposure to
ranolazine.rStudy→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to increase the exposure to
reboxetine. Avoid.oStudy
▶Clarithromycinis predicted to increase the exposure to
regorafenib. Avoid.oStudy
▶Clarithromycinis predicted to increase the exposure to
repaglinide.oStudy
▶Clarithromycinis predicted to increase the exposure to
retinoids(alitretinoin). Adjustalitretinoindose.o
Theoretical
▶Clarithromycinis predicted to increase the exposure to
ribociclib. Avoid or adjustribociclibdose.oStudy→Also
seeTABLE 9p. 849
▶Erythromycinis predicted to increase the exposure to
ribociclib.oStudy→Also seeTABLE 9p. 849
▶Azithromycinincreases the risk of neutropenia when given
withrifabutin.rStudy
▶Clarithromycinincreases the risk of uveitis when given with
rifabutin. Adjust dose.rStudy
▶Erythromycinis predicted to increase the risk of uveitis when
given withrifabutin. Adjust dose.rTheoretical
▶Rifampicindecreases the concentration ofclarithromycin.
rStudy
▶Clarithromycinis predicted to increase the exposure to
risperidone. Adjust dose.oStudy→Also seeTABLE 9
p. 849
▶Clarithromycinis predicted to increase the exposure to
ruxolitinib. Adjust dose and monitor side effects.o
Study
▶Erythromycinis predicted to increase the exposure to
ruxolitinib.oTheoretical
▶Clarithromycinis predicted to increase the exposure to
saxagliptin.oStudy
▶Erythromycinis predicted to increase the exposure to
saxagliptin.nStudy
▶Macrolides(clarithromycin, erythromycin)are predicted to
increase the exposure tosimeprevir. Avoid.rStudy
▶Clarithromycinis predicted to increase the concentration of
sirolimus. Avoid.rStudy
▶Erythromycinincreases the concentration ofsirolimus.
Monitor and adjust dose.oStudy
▶Clarithromycinis predicted to increase the exposure to
solifenacin. Adjustsolifenacinortamsulosin with solifenacin
dose; avoid in hepatic and renal impairment.rStudy
▶Clarithromycinis predicted to moderately increase the
exposure toSSRIs(dapoxetine). Avoid potent inhibitors of
CYP3A4 or adjustdapoxetinedose.rStudy
▶Erythromycinis predicted to increase the exposure toSSRIs
(dapoxetine). Adjustdapoxetinedose with moderate inhibitors
of CYP3A4.oTheoretical
▶Clarithromycinis predicted to increase the exposure tostatins
(atorvastatin). Avoid or adjust dose and monitor
rhabdomyolysis.rStudy
▶Erythromycinis predicted to increase the exposure tostatins
(atorvastatin). Monitor and adjust dose.rStudy▶Clarithromycinmoderately increases the exposure tostatins
(pravastatin).rStudy
▶Erythromycinis predicted to increase the exposure tostatins
(pravastatin).rStudy
▶Clarithromycinis predicted to increase the exposure tostatins
(simvastatin). Avoid.rStudy
▶Erythromycinis predicted to increase the exposure tostatins
(simvastatin). Use with caution and adjustsimvastatindose,
p. 134.rStudy
▶Clarithromycinis predicted to slightly increase the exposure to
sulfonylureas.oTheoretical
▶Clarithromycinis predicted to slightly increase the exposure to
sunitinib. Avoid or adjustsunitinibdose.oStudy→Also
seeTABLE 9p. 849
▶Erythromycinis predicted to increase the exposure to
sunitinib.oTheoretical→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to increase the concentration of
tacrolimus. Monitor and adjust dose.rStudy
▶Erythromycinis predicted to increase the concentration of
tacrolimus.rStudy
▶Clarithromycinis predicted to increase the exposure totaxanes
(cabazitaxel). Avoid.rStudy
▶Erythromycinis predicted to increase the exposure totaxanes
(cabazitaxel).oTheoretical
▶Clarithromycinis predicted to moderately increase the
exposure totaxanes(docetaxel). Avoid or adjust dose.r
Study
▶Clarithromycinis predicted to increase the exposure totaxanes
(paclitaxel).rTheoretical
▶Clarithromycinis predicted to increase the concentration of
temsirolimus. Avoid.rTheoretical
▶Erythromycinis predicted to increase the concentration of
temsirolimus.oTheoretical
▶Erythromycindecreases the clearance oftheophyllineand
theophyllinepotentially decreases the clearance of
erythromycin. Adjust dose.rStudy
▶Macrolides(azithromycin, clarithromycin)are predicted to
increase the exposure totheophylline. Adjust dose.o
Anecdotal
▶Azithromycinis predicted to increase the exposure to
ticagrelor. Use with caution or avoid.rStudy
▶Clarithromycinis predicted to markedly increase the exposure
toticagrelor. Avoid.rStudy
▶Clarithromycinis predicted to increase the exposure to
tofacitinib. Adjusttofacitinibdose.oStudy
▶Erythromycinis predicted to increase the exposure to
tofacitinib.oStudy
▶Clarithromycinis predicted to increase the exposure to
tolterodine. Avoid.rStudy→Also seeTABLE 9p. 849
▶Erythromycinis predicted to increase the exposure to
tolterodine.nTheoretical→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to increase the exposure to
tolvaptan. Adjust dose.rStudy
▶Erythromycinis predicted to increase the exposure to
tolvaptan. Adjust dose.oStudy
▶Macrolidesare predicted to increase the exposure to
topotecan.rStudy
▶Clarithromycinis predicted to increase the exposure to
toremifene.oTheoretical→Also seeTABLE 9p. 849
▶Clarithromycinis predicted to increase the exposure to
trabectedin. Avoid or adjust dose.rTheoretical
▶Macrolidesare predicted to increase the concentration of
trametinib.oTheoretical
▶Clarithromycinis predicted to moderately increase the
exposure totrazodone. Avoid or adjust dose.oStudy
▶Erythromycinis predicted to increase the exposure to
trazodone.oTheoretical
▶Clarithromycinis predicted to increase the exposure to
ulipristal. Avoid if used for uterinefibroids.rStudy
▶Erythromycinis predicted to increase the exposure to
ulipristal. Avoid if used for uterinefibroids.oStudy
▶Clarithromycinis predicted to increase the exposure to
vemurafenib.rTheoretical→Also seeTABLE 9p. 849
▶Azithromycindecreases the exposure tovenetoclax.nStudy950 Macrolides—Macrolides BNFC 2018 – 2019
Interactions|Appendix 1A1